China Pharma Holdings (CPHI) EBIAT (2016 - 2025)
Historic EBIAT for China Pharma Holdings (CPHI) over the last 17 years, with Q3 2025 value amounting to -$651482.0.
- China Pharma Holdings' EBIAT rose 4172.33% to -$651482.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.2 million, marking a year-over-year increase of 3245.82%. This contributed to the annual value of -$4.7 million for FY2024, which is 5383.71% down from last year.
- Latest data reveals that China Pharma Holdings reported EBIAT of -$651482.0 as of Q3 2025, which was up 4172.33% from -$528367.0 recorded in Q2 2025.
- In the past 5 years, China Pharma Holdings' EBIAT registered a high of -$475976.0 during Q1 2023, and its lowest value of -$1.4 million during Q2 2024.
- Over the past 5 years, China Pharma Holdings' median EBIAT value was -$826669.0 (recorded in 2021), while the average stood at -$903544.7.
- In the last 5 years, China Pharma Holdings' EBIAT tumbled by 641855.51% in 2021 and then soared by 6326.01% in 2025.
- China Pharma Holdings' EBIAT (Quarter) stood at -$980719.0 in 2021, then fell by 28.9% to -$1.3 million in 2022, then grew by 2.53% to -$1.2 million in 2023, then grew by 0.63% to -$1.2 million in 2024, then surged by 46.79% to -$651482.0 in 2025.
- Its EBIAT stands at -$651482.0 for Q3 2025, versus -$528367.0 for Q2 2025 and -$800000.0 for Q1 2025.